Sixty seconds on . . . baloxavir

Hawkes, Nigel

doi:10.1136/bmj.k4531

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until then, it should be noted that the effect of baloxavir was at best equivalent to that of oseltamivir. 29 In our study, oseltamivir accounted for about 15% of antiviral prescriptions for influenza, which proportion may be lower than in other countries. There are two plausible reasons.…”

Section: Discussioncontrasting

confidence: 48%

Association of baloxavir marboxil prescription with subsequent medical resource utilization among school‐aged children with influenza

Takeuchi

Kawakami

2021

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose: Baloxavir marboxil is a novel antiviral agent for influenza, introduced into clinical practice in 2018. A concern remains about the variant virus with reduced susceptibility after baloxavir exposure and its clinical consequences such as healthcareseeking behavior. Methods: Using a healthcare database in Japan, we compared the medical resource use following baloxavir and neuraminidase inhibitors (NAIs) treatment among children aged 7-15 years. The study period was from December 2018 to March 2019. The primary endpoint was the composite of hospitalization, laboratory and radiological tests, and antibiotic use over 1-9 days of antiviral treatment. As exploratory analyses, secondary outcomes being each single component of the primary composite were assessed and subgroup analyses comparing baloxavir with each NAI were done. Results: Data from 115 867 prescriptions in 115 238 children were analyzed (median age: 10 years; severe influenza risk in 26%; baloxavir accounting for 43%). Overall, baloxavir use did not increase subsequent medical resource utilization in the composite endpoint (adjusted odds ratio [aOR]: 1.04; 95% confidence interval [CI]: 0.99-1.09; P = 0.14), as were likelihoods of other secondary outcomes. In the subgroup analysis, baloxavir use was associated with higher medical resource use than oseltamivir (aOR: 1.21; 95%

show abstract

Section: Discussioncontrasting

confidence: 48%

Association of baloxavir marboxil prescription with subsequent medical resource utilization among school‐aged children with influenza

Takeuchi

Kawakami

2021

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…Due to its relative recent use in medicine, it is still difficult to provide a strong statement on the interest of BXM [21]. The first approval was in Japan (February 2018), followed by the USA (October 2018), then in Europe (January 2021) for "treating and preventing flu in adults and children from 12 years of age".…”

Section: Medical Interestmentioning

confidence: 99%

Baloxavir Marboxil: An Original New Drug against Influenza

Dufrasne

2021

Pharmaceuticals

View full text Add to dashboard Cite

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir.

show abstract